WATERTOWN, Mass.--(BUSINESS WIRE)--Nov. 22, 2016--
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
the appointment of Lesley Russell, MBChB, MRCPb, to its Board of
Directors. Dr. Russell will also serve as a member of Enanta’s audit
committee and its nominating and corporate governance committee,
effective as of January 1, 2017.
Dr. Russell has over two decades of clinical, regulatory and drug
development expertise in the therapeutic areas of hematology/oncology,
neurology, psychiatry, pain and inflammation, respiratory medicine,
cardiovascular medicine, virology and stem cell therapy. Throughout her
career and under her leadership, she has advanced multiple drug
candidates from preclinical development, through the regulatory approval
“Dr. Russell’s appointment to our Board comes at a critical time as we
seek to expand and advance our development-stage pipeline,” stated Jay
R. Luly, Ph.D. President and Chief Executive Officer. “Her expertise in
clinical and regulatory development will be invaluable as our programs
Dr. Russell currently serves as Chief Medical Officer at Innocoll
Holdings, Plsc., a global, specialty pharmaceutical company, where she
leads the clinical development programs, and medical and regulatory
affairs groups. Prior, she held executive management positions at
TetraLogic Pharmaceuticals, where she held the role of Chief Operating
Officer from 2013 through 2016, and at Teva Pharmaceuticals, where she
was Senior Vice president and Global Head of Research and Development
from 2011-2012. At Teva, she led a team of over 1,500 and was
responsible for all aspects of global drug development. Earlier in her
career, she spent over 10 years at Cephalon, Inc. where she held
positions of increasing responsibility from 2000 -2011, most recently
serving as Executive Vice President and Chief Medical Officer.
Dr. Russell currently serves on the Boards of Directors of AMAG
Pharmaceuticals, Inc. and Endocyte Pharmaceuticals, Inc., public
biotechnology companies, and Melmark, Inc., a non-profit organization
serving adults and children with severe intellectual and physical
Dr. Russell received a MB.Ch.B. degree from the University of Edinburgh,
Scotland, Faculty of Medicine. She is a member of the Royal College of
Physicians, UK, and is registered with the General Medical Council, UK.
Separately, Dr. Ernst-Günter Afting advised the Board of Directors of
Enanta that he will retire as a director effective as of the date of the
2017 annual meeting of stockholders.
Dr. Luly commented, “I want to thank our long-standing board member
Ernst-Günter Afting, M.D., Ph.D., for his many years of guidance and
dedication to Enanta. His significant contributions to the development
of our company are greatly appreciated by all of us at Enanta.”
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta’s
research and development efforts are currently focused on four disease
targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic
Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).
Enanta has discovered novel protease inhibitors that are members of the
direct-acting-antiviral (DAA) inhibitor classes designed for use against
the hepatitis C virus (HCV). These protease inhibitors, developed
through Enanta’s collaboration with AbbVie, include paritaprevir, which
is contained in AbbVie’s marketed DAA regimens for HCV, and glecaprevir
(ABT-493), Enanta’s second protease inhibitor product, which AbbVie has
developed in Phase 3 studies in a fixed-dose combination (G/P) with
pibrentasvir (ABT-530), AbbVie’s second NS5A inhibitor, and is preparing
for regulatory approval filings in the U.S., Europe and Japan.
Enanta has also discovered EDP-305, an FXR agonist product candidate for
NASH, currently in Phase 1 clinical development, as well as a
cyclophilin inhibitor, EDP-494, a novel host-targeting mechanism for
HCV, which is also in Phase 1 clinical development. In addition, Enanta
has early lead candidates for HBV and RSV in preclinical development.
Please visit www.enanta.com
for more information on Enanta’s programs and pipeline.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161122005113/en/
Source: Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc.
MacDougall Biomedical Communications